PL3333166T3 - Proces otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]- 4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran- 4-yloamino)benzamidu - Google Patents

Proces otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]- 4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran- 4-yloamino)benzamidu

Info

Publication number: PL3333166T3
Authority: PL; Poland
Prior art keywords: indazol; ylamino; piperazin; benzamide; pyran
Prior art date: 2012-05-23

Application number

PL17195806T

Other languages

English (en)

Inventor

Natale Alvaro Barbugian

Romualdo Forino

Tiziano FUMAGALLI

Paolo Orsini

Original Assignee

Nerviano Medical Sciences S.R.L.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-23

Filing date

2013-05-22

Publication date

2020-09-07

2013-05-22 Application filed by Nerviano Medical Sciences S.R.L. filed Critical Nerviano Medical Sciences S.R.L.

2020-09-07 Publication of PL3333166T3 publication Critical patent/PL3333166T3/pl

Links

HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL17195806T 2012-05-23 2013-05-22 Proces otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]- 4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran- 4-yloamino)benzamidu PL3333166T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP12169139		2012-05-23
EP17195806.9A EP3333166B1 (en)	2012-05-23	2013-05-22	Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
EP13724270.7A EP2855460B1 (en)	2012-05-23	2013-05-22	Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
PCT/EP2013/060534 WO2013174876A1 (en)	2012-05-23	2013-05-22	Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide

Publications (1)

Publication Number	Publication Date
PL3333166T3 true PL3333166T3 (pl)	2020-09-07

Family

ID=48470987

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL17195806T PL3333166T3 (pl)	2012-05-23	2013-05-22	Proces otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]- 4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran- 4-yloamino)benzamidu
PL17192138T PL3290414T3 (pl)	2012-05-23	2013-05-22	Sposób otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]-4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran-4-yloamino)benzamidu

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL17192138T PL3290414T3 (pl)	2012-05-23	2013-05-22	Sposób otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]-4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran-4-yloamino)benzamidu

Country Status (17)

Country	Link
US (3)	US9085565B2 (pl)
EP (4)	EP3290414B1 (pl)
JP (1)	JP6231556B2 (pl)
KR (1)	KR102151963B1 (pl)
CN (2)	CN106167485A (pl)
AR (1)	AR091138A1 (pl)
AU (2)	AU2013265288B2 (pl)
BR (1)	BR112014028841B1 (pl)
CA (1)	CA2873979C (pl)
ES (2)	ES2751944T3 (pl)
IL (2)	IL235761B (pl)
MX (1)	MX355409B (pl)
NZ (2)	NZ703124A (pl)
PL (2)	PL3333166T3 (pl)
RU (1)	RU2602071C2 (pl)
TW (1)	TWI579280B (pl)
WO (1)	WO2013174876A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE030929T2 (en) *	2007-07-20	2017-06-28	Nerviano Medical Sciences Srl	Substituted indazole derivatives active as kinase inhibitors
CA2952692C (en)	2008-09-22	2020-04-28	Array Biopharma Inc.	Substituted imidazo[1,2b]pyridazine compounds
SG10201900514RA (en)	2008-10-22	2019-02-27	Array Biopharma Inc	Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
BR112012029405B1 (pt)	2010-05-20	2021-01-05	Array Biopharma Inc.	compostos macrocíclicos como inibidores de trk quinase, composição farmacêutica, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação de um composto
EP3290414B1 (en)	2012-05-23	2019-07-24	Nerviano Medical Sciences S.R.L.	Crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
US10407509B2 (en)	2013-07-30	2019-09-10	Blueprint Medicines Corporation	NTRK2 fusions
TWI672141B (zh) *	2014-02-20	2019-09-21	美商醫科泰生技	投予ｒｏｓ１突變癌細胞之分子
IL290905B2 (en)	2014-11-16	2023-09-01	Array Biopharma Inc	Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate
EP3227276B1 (en)	2014-12-02	2021-09-01	Ignyta, Inc.	Combinations for the treatment of neuroblastoma
US20170356918A1 (en) *	2014-12-03	2017-12-14	Ignyta, Inc.	Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
HK1253093A1 (zh)	2015-06-01	2019-06-06	Loxo Oncology Inc.	诊断和治疗癌症的方法
KR20240115937A (ko) *	2015-07-02	2024-07-26	아세르타 파마. 비.브이.	(S)-4-(8-아미노-3-(1-(부트-2-이노일)피롤리딘-2-일)이미다조[1,5-a]피라진-1-일)-N-(피리딘-2-일)벤즈아마이드의고체 형태 및 제제
EP3322706B1 (en)	2015-07-16	2020-11-11	Array Biopharma, Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2017075107A1 (en)	2015-10-26	2017-05-04	Nanda Nisha	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN108697661A (zh)	2015-12-18	2018-10-23	亚尼塔公司	用于治疗癌症的组合
TN2019000332A1 (en)	2016-04-04	2021-05-07	Loxo Oncology Inc	Methods of treating pediatric cancers
EP3439662B1 (en)	2016-04-04	2024-07-24	Loxo Oncology, Inc.	Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
LT3800189T (lt)	2016-05-18	2023-10-10	Loxo Oncology, Inc.	(s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroksipirolidin-1-karboksamido gavimas
AU2017271458B2 (en)	2016-05-24	2020-11-26	Nerviano Medical Sciences S.R.L.	New crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar)	2016-10-10	2019-04-09	Array Biopharma Inc	مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
AU2018207464B2 (en)	2017-01-10	2020-05-14	Novartis Ag	Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
CN110267960B (zh)	2017-01-18	2022-04-26	阿雷生物药品公司	作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
IL271759B2 (en)	2017-07-19	2024-01-01	Ignyta Inc	Pharmaceutical compositions comprising entrectinib
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh)	2017-10-10	2025-03-11	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3697390A1 (en)	2017-10-17	2020-08-26	Ignyta, Inc.	Pharmaceutical compositions and dosage forms
MA50456A (fr)	2017-10-26	2020-09-02	Array Biopharma Inc	Formulations d'un inhibiteur de kinase trk macrocyclique
CA3087972C (en)	2018-01-18	2023-01-10	Array Biopharma Inc.	Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3087578C (en)	2018-01-18	2023-08-08	Array Biopharma Inc.	Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CA3087354C (en)	2018-01-18	2023-01-03	Array Biopharma Inc.	Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3095366A1 (en)	2018-03-29	2019-10-03	Loxo Oncology, Inc.	Treatment of trk-associated cancers
KR102653681B1 (ko)	2018-07-31	2024-04-03	록쏘 온콜로지, 인코포레이티드	(s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
ES2922314T3 (es)	2018-09-10	2022-09-13	Array Biopharma Inc	Compuestos heterocíclicos condensados como inhibidores de cinasa RET
EP3898615A1 (en)	2018-12-19	2021-10-27	Array Biopharma, Inc.	7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
JP2022515198A (ja)	2018-12-19	2022-02-17	アレイバイオファーマインコーポレイテッド	ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
AU2020319662B2 (en)	2019-07-31	2024-02-29	F. Hoffmann-La Roche Ag	New pharmaceutical formulation
US20220372024A1 (en) *	2019-11-01	2022-11-24	Johnson Matthey Public Limited Company	Crystalline forms of entrectinib
CN113024521B (zh) *	2019-12-09	2023-01-17	武汉九州钰民医药科技有限公司	一种制备恩曲替尼的方法
CN111171009B (zh) *	2020-01-10	2022-07-12	安礼特（上海）医药科技有限公司	恩曲替尼晶型及其制备方法
CN113354626B (zh) *	2020-03-04	2025-06-03	罗欣药业(上海)有限公司	恩曲替尼的晶型及其制备方法
CN113801062B (zh) *	2020-06-15	2023-05-26	沈阳药科大学	3-氨基-5-(3,5-二氟苄基)-1h-吲唑的制备方法
CN116669735B (zh) *	2021-02-03	2026-02-06	齐鲁制药有限公司	恩曲替尼晶型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI58125C (fi) *	1976-12-15	1985-01-02	Orion Yhtymae Oy	Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolin med blodtryckssaenkande vekan
DE19730989A1 (de) *	1997-07-18	1999-01-21	Merck Patent Gmbh	Piperazin-Derivate
EA017852B1 (ru) *	2006-12-20	2013-03-29	НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.	Производные замещенных индазолов, активные в качестве ингибиторов киназ
HUE030929T2 (en) *	2007-07-20	2017-06-28	Nerviano Medical Sciences Srl	Substituted indazole derivatives active as kinase inhibitors
JP5580332B2 (ja) *	2008-12-18	2014-08-27	ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ	キナーゼ阻害剤として活性な置換インダゾール誘導体
EP3290414B1 (en)	2012-05-23	2019-07-24	Nerviano Medical Sciences S.R.L.	Crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide

2013
- 2013-05-22 EP EP17192138.0A patent/EP3290414B1/en active Active
- 2013-05-22 PL PL17195806T patent/PL3333166T3/pl unknown
- 2013-05-22 CA CA2873979A patent/CA2873979C/en active Active
- 2013-05-22 EP EP17195806.9A patent/EP3333166B1/en active Active
- 2013-05-22 TW TW102118026A patent/TWI579280B/zh active
- 2013-05-22 PL PL17192138T patent/PL3290414T3/pl unknown
- 2013-05-22 ES ES17192138T patent/ES2751944T3/es active Active
- 2013-05-22 EP EP13724270.7A patent/EP2855460B1/en not_active Withdrawn - After Issue
- 2013-05-22 KR KR1020147036163A patent/KR102151963B1/ko active Active
- 2013-05-22 AU AU2013265288A patent/AU2013265288B2/en active Active
- 2013-05-22 BR BR112014028841-0A patent/BR112014028841B1/pt active IP Right Grant
- 2013-05-22 MX MX2014013924A patent/MX355409B/es active IP Right Grant
- 2013-05-22 ES ES17195806T patent/ES2771100T3/es active Active
- 2013-05-22 JP JP2015513159A patent/JP6231556B2/ja active Active
- 2013-05-22 NZ NZ703124A patent/NZ703124A/en unknown
- 2013-05-22 EP EP19188774.4A patent/EP3581571A1/en not_active Withdrawn
- 2013-05-22 NZ NZ716487A patent/NZ716487A/en unknown
- 2013-05-22 WO PCT/EP2013/060534 patent/WO2013174876A1/en not_active Ceased
- 2013-05-22 RU RU2014151565/04A patent/RU2602071C2/ru active
- 2013-05-22 CN CN201610455414.2A patent/CN106167485A/zh active Pending
- 2013-05-22 CN CN201380026532.6A patent/CN104395308B/zh active Active
- 2013-05-23 AR ARP130101795 patent/AR091138A1/es unknown
2014
- 2014-10-30 US US14/528,475 patent/US9085565B2/en active Active
- 2014-11-18 IL IL235761A patent/IL235761B/en active IP Right Grant
2015
- 2015-05-20 US US14/716,986 patent/US9382235B2/en active Active
2016
- 2016-06-03 US US15/172,478 patent/US9649306B2/en active Active
2018
- 2018-02-13 AU AU2018201037A patent/AU2018201037B2/en active Active
- 2018-06-27 IL IL260297A patent/IL260297A/en unknown

Also Published As

Publication number	Publication date
US20160279125A1 (en)	2016-09-29
NZ716487A (en)	2017-01-27
MX2014013924A (es)	2015-02-17
US9649306B2 (en)	2017-05-16
BR112014028841B1 (pt)	2021-01-12
TW201400479A (zh)	2014-01-01
TWI579280B (zh)	2017-04-21
IL235761B (en)	2018-07-31
AR091138A1 (es)	2015-01-14
US9382235B2 (en)	2016-07-05
EP3333166B1 (en)	2019-11-06
EP3581571A1 (en)	2019-12-18
MX355409B (es)	2018-04-18
RU2014151565A (ru)	2016-07-20
US9085565B2 (en)	2015-07-21
JP6231556B2 (ja)	2017-11-15
EP2855460B1 (en)	2017-11-08
JP2015517551A (ja)	2015-06-22
US20150051222A1 (en)	2015-02-19
ES2771100T3 (es)	2020-07-06
CN104395308A (zh)	2015-03-04
ES2751944T3 (es)	2020-04-02
US20150274707A1 (en)	2015-10-01
HK1207077A1 (en)	2016-01-22
IL260297A (en)	2018-08-30
EP2855460A1 (en)	2015-04-08
AU2013265288A2 (en)	2015-01-29
NZ703124A (en)	2016-07-29
KR102151963B1 (ko)	2020-09-07
CA2873979C (en)	2019-11-12
AU2013265288A1 (en)	2015-01-22
EP3290414A1 (en)	2018-03-07
AU2013265288B2 (en)	2017-12-21
RU2602071C2 (ru)	2016-11-10
AU2018201037B2 (en)	2019-07-04
PL3290414T3 (pl)	2020-01-31
CA2873979A1 (en)	2013-11-28
AU2018201037A1 (en)	2018-03-01
KR20150016352A (ko)	2015-02-11
CN104395308B (zh)	2016-08-24
CN106167485A (zh)	2016-11-30
EP3333166A1 (en)	2018-06-13
WO2013174876A1 (en)	2013-11-28
EP3290414B1 (en)	2019-07-24
IL235761A0 (en)	2015-02-01
BR112014028841A2 (pt)	2017-06-27

Publication	Publication Date	Title
IL260297A (en)	2018-08-30	Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide
ZA201404881B (en)	2015-12-23	Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
IL263004B (en)	2022-04-01	A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide
ZA201402907B (en)	2015-04-29	Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
SI2771329T1 (sl)	2016-07-29	Nove disubstituirane 3,4-diamino-3-ciklobuten-1,2-dion-spojine za uporabo pri tretiranju kemokin mediiranih bolezni
PL2987791T3 (pl)	2020-03-31	Pochodna kwasu 3-(4-benzyloksy(fenylo)heks-4-ynowego odpowiednia do zapobiegania i leczenia chorób metabolicznych
IL233937A (en)	2016-04-21	Process for making phenyl-3-diphloromethyl-1-methyl-1h-pyrazole-4-carboxylic-n-methoxy-[1-methyl-2-phenylethyl] amide
FR2988609B1 (fr)	2015-09-04	Formulation pour l'hormonotherapie
PL2901857T3 (pl)	2017-08-31	Sposób wytwarzania 3-chloro-4,5,6-trifluoro-pikolinonitrylu
ZA201504601B (en)	2016-10-26	Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h-pyrazol-3-ylamine
HUP1100351A2 (en)	2012-12-28	Process for the preparation of (5alpha,17beta)-n-[2,5-bis-(trifluoromethyl)-phenyl]-3-oxo-4-aza-5-androst-1-en-17-carboxylic amide
PT2981518T (pt)	2021-06-04	Um processo melhorado para a preparação de maleato de fluvoxamina
IL238829B (en)	2018-02-28	Process for the preparation of 4-(cyclopropylmethoxy-3,5)-n-(dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide
ZA201601750B (en)	2017-08-30	Tramadol hydrochloride and paracetamol orally disintegrating composition and process for preparing the same
HUE043092T2 (hu)	2019-08-28	Eljárás l-[2-(2,4-dimetil-fenilszulfanil)-fenil]-piperazin elõállítására
PL394344A1 (pl)	2012-10-08	Inhibitor wychwytu zwrotnego serotoniny, jego zastosowanie i sposób syntezy
PL390553A1 (pl)	2011-08-29	Sposób otrzymywania 1,2-epoksybutan-3-olu
PL390554A1 (pl)	2011-08-29	Sposób otrzymywania 2,3-epoksybutan-1-olu